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Epilepsy is one of the most important neurological diseases. It concerns about 1% of the population
worldwide. Despite the discovery of new molecules, one third of epileptic patients are resistant to anti-
epileptic drugs and among them only a few can beneﬁt from resective surgery. In this context, radio-
therapy is an interesting alternative to the other treatments and several clinical devices exist (e.g.,
Gamma Knife®). The European Synchrotron Radiation Facility offers the possibility to develop new
methods of radiosurgery and to study their antiepileptic effects. Here, we discuss several studies that we
performed recently to test and try to understand the antiepileptic effects of X-ray synchrotron micro-
beams in different animal models of epilepsy. We showed a decrease of seizures after Interlaced
Microbeam Radiotherapy (IntMRT) of the somatosensory cortex, known as the seizure generator, in a
genetic model of absence epilepsy. These antiepileptic effects were stable over 4 months and with low
tissular and functional side-effects. The irradiated pyramidal neurons still displayed their physiological
activity but did not synchronize anymore. We also obtained a lasting suppression of seizures after
IntMRT of the dorsal hippocampus in a mouse model of mesiotemporal lobe epilepsy. However, an
important variability of antiepileptic efﬁciency was observed probably due to the small size of the tar-
geted structure. Despite these encouraging proofs-of-concepts, there is now a need to adapt IntMRT to
other models of epilepsy in rodents which are close to refractory forms of epilepsy in human patients and
to implement this approach to non-human primates, before moving to clinical trials.
© 2015 Published by Elsevier Ltd on behalf of Associazione Italiana di Fisica Medica. This is an open
access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).The epilepsies and the need for new therapies
Epilepsy is a devastating multi-causal chronic disease charac-
terized by recurrent spontaneous seizures and affects about 1% of
the population worldwide. This represents about 3 million people
in Europe which implies an annual cost of 15.5 billion euros [1].
Although epilepsy is deﬁned by the presence of recurrent seizures,
it is often associated with comorbid abnormalities in cognition,Neurosciences, Centre de
aculte de Medecine, Domaine
e, France. Tel.: þ33 04 56 52
A. Depaulis).
alf of Associazione Italiana di Fisicpsychiatric status, and social-adaptive behavior, as well as with an
increased risk of mortality. This is especially true in drug-resistant
epilepsies, which represent a socioeconomic burden at the indi-
vidual, familial, societal and political levels in all countries across
the globe. Drug-resistant epilepsies account for about one third of
adult epileptic patients. Among them, some may beneﬁt from
resective surgery of the epileptogenic zone. Indeed, complete
seizure freedom can be obtained by neurosurgical resective surgery
with a rate of success of about 42% 5 years after resection to 33% 10
years later [2]. Resective surgery is currently the gold-standard
treatment capable of suppressing drug-resistant seizures [3]. But
surgery requires that the epileptic zone is (i) focal, (ii) clearly
identiﬁed and (iii) can be safely removed [4]. This is a rather rare
combination and only a limited number of patients can indeed
beneﬁt from such a surgical approach. The development ofa Medica. This is an open access article under the CC BY-NC-ND license (http://
Figure 2. Histological section of pig cerebellum 15 months after MB (20e30 mmwide,
210 mm apart) irradiation performed with an entrance dose of 300 Gy (HE staining).
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increase the number of drug-resistant patients that could be cured
from their focal epilepsy. In this context, our consortium has
investigated for the last 5 years the effects of synchrotron
microbeam-based therapies to suppress seizures in animal models.
In this chapter, we review our work and discuss the perspectives of
this approach.
The use of microbeams
Radiosurgery represents one of the most promising alternative
to resective surgery. Indeed, modern radiosurgical devices such as
Gamma Knife® and Cyberknife® [5] have provided satisfying results
in treating various types of epilepsies associated with arterio-
venous malformations, cavernomas, tumors, mesio-temporal scle-
rosis and hypothalamic hamartomas (see Ref. [6] for review).
However, the reported failures in radiosurgical treatment of
epileptic foci are often correlated with the radiosensitivity of
normal tissues surrounding the lesion, which sets the limit to the
radiation dose that can be safely delivered within the target [7,8].
The lateral dose gradients from the irradiated target to surrounding
sensitive structures which are achievable with high-energy pho-
tons (MeV range) display a broad distribution of dose (Fig. 1), thus
preventing delivery of high enough and curative doses to the target
without injuring functional adjacent structures. The low-energy
photons (keV) generated by 3rd generation synchrotron sources
offer an adequate dose rate, energy spectrum and a minimal beam
divergence which allows the deposition of extremely steep lateral
dose fall-off (Fig. 1) [9]. Therefore, synchrotron X-ray radiosurgery
provides sufﬁcient precision to perform experimental studies in
animal models of epilepsy, which is unachievable using conven-
tional megavoltage radio-oncologic devices used in hospitals.
The use of spatial fractionation of ionizing radiation in the
microscopic range was ﬁrst reported at the end of the ﬁfties
[10e13]. A 25 mm-wide deuteron microbeam failed to elicit visible
cerebral damage in mice unless absorbed doses were over 3000 Gy;
the deuterons, however, reached only 1.5 mm tissue depth. The
recent availability of microplanar 50e150 keV synchrotron-
generated x-ray beams (microbeams or MB) produces sharply
deﬁned beam edges deep in the tissues and with a high dose rate
[14]. This has led to investigate the effects of MB on murine brains,
using arrays of quasi parallel 25e75 mm-wide beam slices spaced
50e200 mm on center [15]. The tissue lesions resembled those
induced by deuteron MB [11,12]. Surprisingly, animals withstood
absorbed doses of hundreds, even thousands of gray from x-rays
delivered to microscopic slices of their brains [16]. Tissue damage
(i.e., cellular death) was conﬁned to the MB paths. For example,
adult cerebellum of pigs irradiated as weanling piglets showed
stripes of cell loss restricted to the MB tracts [17] (Fig. 2). All irra-
diated pigs developed normally and never displayed any behavioral
or developmental adverse effects.Figure 1. Lateral dose-proﬁles for a 5 mm-wide irradiation ﬁeld produced by inter-
laced and non-interlaced MB and by a Leksell Perfexion® Gamma-Knife.Recently, we introduced a novel use of MB: by rotating the brain
around a center of rotation using a goniometer, we precisely in-
terlaced MB to deposit a high homogeneous radiation dose into
discrete brain regions [18], with no extensions on neighboring
tissue [18] (Fig. 3). This irradiation procedure, which allows a lateral
dose fall-off about 200 times greater than conventional radio-
therapy [18], was called Interlaced Microbeam Radiotherapy
(IntMRT). The submillimetric precision of targeting, combined with
the preservation of surrounding tissues, makes IntMRT clinically
attractive for all pathologies that require circumscribed destruc-
tion, inactivation and/or disconnection of small brain regions, even
if close to eloquent or vital structures.
First proof of concept of IntMRT in a genetic model of epilepsy
in the rat
Short term functional effects
The efﬁciency of IntMRT is currently veriﬁed in rodent brain
tumor treatment but this novel approach of high dose delivery
appeared relevant for non-cancerous brain disease therapies. In
2010, we established a collaboration which aimed at evaluating
IntMRT efﬁcacy on epileptic tissue. Our working hypothesis was
based on the fact that several studies in patients [19,20] and animal
models [21e23] suggested that an antiepileptic effect could be
obtained even if the irradiation did not result in necrosis of the
targeted structure. This non-necrotizing radiotherapeutic effect
was believed to be caused by biochemical alterations and neuro-
modulation, although the cellular mechanisms remained elusive
[20,24]. One of the prerequisites was to target an epileptic tissue
withwell-identiﬁed neurons generating seizures and presenting no
cell loss and/or sclerosis to avoid confounding factors, thus allow-
ing the assessment of radiation-induced changes. For these reasons,
we chose to ﬁrst perform IntMRT in the Genetic Absence Epilepsy
Rats from Strasbourg (GAERS) [25]. The GAERS has emerged as a
well-recognized and studied rat model for idiopathic generalized
epilepsy with absence seizures. Many studies have characterized its
behavioral, electrophysiological, pathophysiological and pharma-
cological features, which closely resemble human absence seizures
[26,27]. GAERS display very stable spontaneous spike-and-wave
discharges (SWD) on the cortical electroencephalogram (EEG)
accompanied by simultaneous behavioral arrest, characteristic of
absence seizures. In addition, the model allows both long term
Figure 3. A. Average color-coded map of the absence seizure foci in GAERS rats (n ¼ 6) obtained from subdural multielectrode recordings. Hot colors represent the location of the
drivers of spike-wave discharges based on non-linear association analyses (H2). BeC. 3D representation of the microbeam interlacement. The volume receiving a homogeneous dose
is depicted in grey. D. Coordinates of the irradiation targets superimposed to the corresponding rat brain stereotactic atlas plates [30]. E. Two-week post-irradiation T1w/Gadolinium
MR image showing the sharply delimited hypersignals in the bilateral somatosensory cortices, juxtaposed to the corresponding atlas plate. (For interpretation of the references to
colour in this ﬁgure legend, the reader is referred to the web version of this article.)
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neurons [28].
Recently, we showed in the GAERS that the SWD are initiated in
the somato-sensory cortex and then spread rapidly to the motor
cortex and the ventrobasal thalamus [28,29]. We therefore targeted
these three brain regions. In order to precisely irradiate the brain
volume of each of these regions, we positioned anaesthetized
GAERS rats on a Plexiglas stereotactic frame mounted on micro-
metric motors, allowing movements and rotations in the 3 di-
mensions. The bregma, at the junction of the frontal and parietal
bones, was clearly visualized on the x-ray reconstructed image of
the rat's head and used to deﬁne the coordinates [30] of irradiation
ﬁelds. Then, the beam was spatially fractionated into an array of
parallel microbeams (50 mmwide, 200 mm on-center distance) by a
multislit collimator. Each side of the targeted brain regions was
irradiated using 4 ports separated by a 45 angle and a 50 mm step,
to generate a solid dose deposition at the interlaced region (Fig. 3).
The nominal dose deposited within the target was ﬁxed at 200 Gy
(according to Monte Carlo simulations [31]). In each animal, we
veriﬁed the correct targeting by T1-weighed magnetic resonance
imaging (MRI) within the two weeks that followed IntMRT and
examined their general behavior by standard tests to detect
possible side effects. We also euthanized some irradiated animals
for histological analysis, using Nissl stains and stains for myelin
sheaths. Outside the interlaced target, the microbeam tracks were
visible in the striatum and the S1 cortex (Fig. 4B) on histological
brain sections obtained two months after irradiation, as thin clear
stripes alternating with darker, nominally non-irradiated tissue
swathes z200 mm spaced apart. Radiation effects were also
conﬁrmed on immuno-labeled slices for NeuN, GFAP, Type IV
collagen, RECA and GLUT-1, respectively markers of neurons,astrocytes, basal lamina, angiogenesis and glucose transporter. MRI
controls done 2 weeks after irradiation conﬁrmed the accuracy of
radiation targeting and the minimal changes in surrounding tis-
sues, as shown by localized increase in contrast-agent diffusion on
MRI (Figs. 3E and 4A). Similarly, histopathological controls revealed
minor structural tissue disruptions in the short-term post-irradia-
tion phase (2 months) (Fig. 4B). It is important to note that although
eloquent cortex was targeted bilaterally, no signiﬁcant behavioral
alterations were measured (Rotarod®, open-ﬁeld) in the acute (2
weeks) post-irradiation phase. Altogether these controls conﬁrmed
that IntMRT has limited short-term deleterious effects on brain
tissue and does not lead to strong motor or cognitive impairments
up to two months after irradiation.
During the 4 months that followed irradiation, we monitored
absence seizures weekly, in freely-moving animals, by recording
local-ﬁeld potentials (LFP) from depth electrodes implanted in the
three target regions. These recordings showed that MB irradiation
suppressed SWD when the somatosensory cortex was irradiated
(Fig. 3C). While non-irradiated cortical and thalamic regions could
still produce epileptic discharges, the irradiated volume became
isolated from the pathological activity. In contrast, MB irradiation of
the motor cortex or ventrobasal thalamus did not signiﬁcantly
suppress SWD [25]. The mechanisms of the functional exclusion of
the somatosensory cortex were further investigated by individually
recording irradiated neurons two months after irradiation using
in vivo intracellular electrophysiological recordings, as previously
used [28]. This approach revealed that the irradiated pyramidal
neurons were strongly hyperpolarized, displayed a decreased
excitability and a reduction of spontaneous synaptic activities [25]
(Fig. 4C). These functional alterations may explain the suppression
of paroxysmal oscillations within irradiated cortical networks
Figure 4. A. Contrast agent enhanced T1 MR image acquired 14 days after a bilateral irradiation of the somatosensory cortex. Irradiated volume geometry is delimited in red. Brain
structures (Mo: Motor cortex; S1: primary somatosensory cortex; CPu: Caudate Putamen nuclei) are superimposed to the MR image. B. Nissl (two left panels) and myelin staining
(two right panels) of irradiated and non-irradiated cortical tissue two months posttreatment. Electrophysiological characterization of irradiated and control neurons from the deep
layers of the somatosensory cortex (red dots on MR image): interictal (C) and ictal (D) activities showing a reduction of action potential frequency and a hyperpolarization in
irradiated neurons, as well as a loss of synchronized activities during seizures. From Ref. [21]. (For interpretation of the references to color in this ﬁgure legend, the reader is referred
to the web version of this article.)
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electrophysiological recordings of individual neurons. As such,
these recordings are a preliminary and critical step towards un-
derstanding how ionizing radiation energy delivery impacts
neuronal physiology and physiopathology. Indeed, our data should
provide clues on how radiation dose should be delivered for tar-
geting epileptic neuronal networks.
Long-term histological effects
Our experiment provided evidence of moderate histological
consequences at 2 months post-irradiation. Nevertheless, long-
term risks (one year or more) associated with the delivery of
quasi-seamless doses into restricted brain regions should not be
minimized. Indeed, the extent of normal tissue damage induced by
moderate doses delivered by MB depends to a large extent on
spatial fractionation. IntMRT delivers a high radiation dose almost
homogeneously to a submillimetric well-delimited brain volume
[18]. In a normal brain, such lesions display short-termMRI features
indicative of a disruption of the blood-brain barrier [32]. Few data
are yet available on long-term consequences of IntMRT in the brain.
Even low doses of seamless irradiation delivered by a single broad
beam elicit late vascular and parenchymal necrosis in the central
nervous system of laboratory animals, mostly as a consequence of
arterionecrosis [33]. Stereotactic irradiation of the frontal cerebral
lobes of normal rats with 2 or 3 mm sized collimators and doses of
30e50 Gy result in radiation necrosis about 19 months afterexposure [34]. Such observations temper against premature as-
sessments of damage to the central nervous system by homoge-
neous irradiations. Preliminary data in two rats revealed delayed
focal necrotizing arteritic lesions and ensuing cerebral infarction in
the target regions 6 months after IntMRT that likely developed
weeks before the rats' death (Fig. 5). We can hypothesis that by
irradiating a smaller brain volume it should be possible to avoid the
biggest brain vessels and prevent these vascular damages.
Application of IntMRT to other animal models
GAERS models absence-epilepsy, a form of epilepsy that is well
controlled by anti-epileptic drugs, disappears in most patients at
adulthood and probably would never be a candidate for clinical
IntMRT. Therefore, we are currently applying IntMRT to other ani-
mal models of epilepsy with focal seizures and that are reminiscent
of epilepsies that would be candidates for such therapies.
Mesiotemporal lobe epilepsy model in mice
We ﬁrst applied IntMRT to a mouse model of mesiotemporal
lobe epilepsy (MTLE). This syndrome classically occurs in human
patients several years after an initial precipitating insult (e.g.,
complex febrile seizures). The ﬁrst seizures are generally well
controlled by antiepileptic drugs (AED) but often becomemedically
refractory. The focal seizures are characterized by a motionless
stare and oro-alimentary automatisms (e.g., lip smacking, chewing)
Figure 5. A, B: Coordinates for IntMRT targeting S1 Cortex (A) and thalamus (B). CeE: Necropsy of GAERS rats at 6 months after IntMRT. Histologic sections: Necrotizing arteritis
(leptomeningeal artery, C and E) with subacute perifocal inﬂammation and hemosiderosis in the irradiated cortical S1 region (E). The damage to the cortex is moderate, in contrast
to the extensive, organizing cystic macroscopic lesion with hemorrhage and brain tissue necrosis seen in the irradiated thalamus of another rat (D, millimetric scale), where
ﬁbrinoid vascular changes were also present.
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generalized. In addition to these clinical features, the MTLE syn-
drome is generally associated with a hippocampal sclerosis, mainly
characterized by a selective neuronal loss in the CA1/CA3 and hilus
area and a proliferation of astroglial cells within the Ammon's horn
of the hippocampus and the hilus of the dentate gyrus (for review
see [35]).
MTLE is the principal indication for resective surgery. Actually,
about 2/3 of patients that undergo this procedure are patient
suffering drug-refractory MTLE [36]. The procedure consists in
surgically removing the seizure onset zone, generally the hippo-
campus, after functional exploration using depth electrodes. This
surgery has an excellent track record showing that the hippocam-
pus can be safely removed with minimal deleterious functional and
behavioral consequences. Thus, MTLE appeared as the most logical
target for a proof-of-concept application of IntMRT on drug-
resistant focal epilepsy.
Several animal models of this syndrome have been developed in
rats and mice (for review see Depaulis & Hamelin2015 [37]).
Among them intrahippocampal injection of kainate in mice was
shown to induce ipsilateral excitotoxic damages (i.e., cell loss in
CA1, CA3 and dentate gyrus hilus) during the 2e3weeks that follow
the injection, as well as proliferation and hypertrophy of astrocytes
and microglia, sprouting of the mossy ﬁbers and dispersion and
hypertrophy of neurons of the dentate gyrus [38e40]. These
changes are restricted to the injected hippocampus and show a
great similarity to the most severe type of hippocampal sclerosis,
observed in up to 80% of mesial-temporal lobe resections from
MTLE patients [35]. In this model, spontaneous seizures with a
hippocampal onset occur regularly and remain stable in frequency
and duration for months [39]. These recurrent seizures are mostly
conﬁned to the ipsilateral hippocampus with contralateral spread
in some animals, but very rare generalizations to the cortex.
In order to assess the feasibility and effect of IntMRT on this
model, we ﬁrst injected kainate into the right hippocampus of
C57Bl6 mice, and then placed custom-made bipolar carbonelectrodes (MRI compatible) in this structure. Baseline hippocam-
pal recordings were acquired after the four-week epileptogenesis
period and focal seizures were quantiﬁed. Then, we applied IntMRT
to the ipsilateral dorsal hippocampus which was shown to generate
seizures [41]. Among the 8 mice irradiated at 100 Gy which dis-
played seizures before irradiation (Fig. 6A) two presented a
decrease of focal seizures at 3 weeks post-irradiation and a com-
plete suppression at 2 and 4 months (Fig. 6C). Two other mice
showed a decrease of seizures at 4 months post irradiation. The
remaining 4 irradiated epileptic mice did not present any signiﬁ-
cant decrease of seizures despite histologically identiﬁable traces of
MB (Fig. 6B) and MRI evidence of correct targeting. This lack of
efﬁciency in 50% ofmicemust be pondered by the fact that epileptic
hippocampus of a MTLE mouse is by deﬁnition small, irregularly
shaped and located below the cortical surface. The fact that we
managed to suppress seizures in 25% of the animal with no obvious
deleterious behavioral effect is however encouraging to try other
MRT protocols.
Current and future animal experiments
From our experience with GAERS rats and MTLE mice, we
concluded that IntMRT is a unique tool that allows the deposition of
high doses of radiation in restricted volumes with such a precision
that a mouse hippocampus can be targeted. However, the conse-
quences of seamless irradiation are not exempt of long-term risks.
We therefore decided to pursue our future experiments using the
IntMRT method but in such a fashion that only parts of the volume
are irradiated. Used as such IntMRToffers the best of twoworlds: (i)
the deposition of high restricted doses through the MB interlace-
ment, and (ii) the preservation of the vascular system by fraction-
ated irradiations.
Our goal is now to assess the antiepileptic effect of this reﬁned
IntMRTmethod using models of refractory neocortical epilepsies in
rats. Indeed, in human this type of epilepsy is frequently resistant to
AED, displays considerable comorbidities [42,43] and is surgically
Figure 6. A. Electroencephalographic recordings from a mesiotemporal lobe epilepsy mice model before irradiation (top trace) and after IntMRT irradiation of the epileptic hip-
pocampus (bottom trace). B. Nissl staining of an irradiated MTLE mice displaying the MB traces. C. Effect of IntMRT on focal hippocampal seizures in MTLE mice at 100 Gy (white
squares, n ¼ 8) and 0 Gy (black dots, n ¼ 3). Note that given the electrode technology it was not always possible to record all the mice.
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cortical area.
Towards clinical applications
IntMRT should offer possible clinical applications and our con-
sortium is currently developing pre-clinical studies towards that
purpose. However, implementing IntMRT for epileptic patients is
not a trivial issue and several aspects need to be addressed when
considering the possibilities to develop IntMRT for clinical
applications.
Which forms of epilepsy could beneﬁt from IntMRT?
Resective surgery is currently the gold standard to treat efﬁ-
ciently and even cure patients with refractory epilepsies associated
with focal seizures [36]. It has been greatly developed over the last
twenty years due to improvements of neuroimaging, electrophys-
iological and neuropsychological technics (for review see Romanelli
et al., 2012 [44]). Yet, such resections are not possible when the
epileptogenic zone is close to or belongs to an eloquent cortex area
as it would lead to dramatic neurological complications. Similarly,
resection of multiple epileptic foci or subcortical ones are difﬁcult
and highly risky to perform. These forms of epilepsies are already
being treated by stereotactic radiosurgical procedures using
Gamma- or Cyber-Knife®, in particular when epilepsy is secondary
to brain tumors (e.g., arteriovenous malformation, cavernomas;
[44]) or hypothalamic hamartomas [45]. Such techniques have also
been shown to be efﬁcient for mesiotemporal lobe epilepsy with
favorable outcomes [46]. IntMRT will therefore ﬁrst target these
forms of epilepsies for which it would beneﬁt from the experience
of radiosurgery. Applying IntMRT to a brain area that will be later
removed by surgical resection will very likely be a strategy for a
proof-of-concept clinical trial in order to collect anatomical and
functional information on the resected tissue to better understand
the consequences of irradiation, while reducing the risks for the
patients. Given our ﬁrst data in animal models, it is likely that
IntMRT will improve radiosurgical treatment of refractory epi-
lepsies and/or reduce their side-effects. In addition to epilepsies
associated with focal seizures, IntMRT should also allow to consider
drug-resistant or difﬁcult to treat generalized epilepsies such as theLandau-Kleffner syndrome, a severe form of child epilepsy which is
associated with aphasia and continuous spike-and-wave during
sleep [47]. For this particular syndrome, multiple subpial transec-
tions have been proposed [48] which aim at disconnecting hori-
zontal interneurons to reduce the synchronization of principal
ones. Although good outcomes have been obtained [49] using this
technic, it is greatly invasive and represents an important risk for
the patients. IntMRT, by allowing very precise deposition of high
doses should allow to reproduce subpial transection and/or the
speciﬁc alteration of horizontal interneurons. Proof-of-concept
experiments in animal models should allow us to determine
whether IntMRT could be used for such approach.
The need for other mammalian models
Although quite challenging, it is necessary to develop methods
which allow the irradiation of larger brains such as those of human
patients. In the case of epilepsy, the application of high-ﬂux frac-
tionated MB in mammalian models other than rodents appears
necessary before considering its application to humans. Indeed,
such trials should provide evidence for antiepileptic effects of MB in
species with larger brain volume andmore complex symptoms and
comorbidities associated with the epilepsy. One major issue for a
clinical application is to take into account the complex shape of the
human cortex, i.e. the gyri and sulci forming the cortical convolu-
tions. This is indeed a real challenge as the angle of irradiation may
vary according to the localization of the cortical focus to target. To
this aim the use of non-human primates appears the most appro-
priate as their cortical architecture and somatotopic arrangement is
closer to human patients [50]. Furthermore, predictive models of
epilepsy have been described in macaques which should allow
preclinical evaluation of the efﬁcacy of MB [51,52]. In addition, such
models would be more efﬁcient to address the behavioral side ef-
fects of synchrotron MB irradiation, since sophisticated behavioral
and cognitive tests exist in non-human primates which are much
closer to human competencies than in other mammalian species.
For instance, when MB irradiation targets a brain region dedicated
to the motor control of the hand, behavioral tests exists in non-
human primate to quantify the hand dexterity [53], a critical con-
trol that cannot be addressed in other species. The use of non-
human primates should, however, be limited as much as possible
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signiﬁcance [54]. This can be envisioned at ESRF because of the
existing irradiation infrastructures including an advanced patient
safety system, the availability of suitable x-ray microbeams, the
presence of skilled personnel and the availability of a biomedical
facility near the irradiation room. Indeed, to develop new irradia-
tion therapies it is critical to combine a clinical expertise in the
surgery and radiosurgery of epilepsy.
Dosimetric and safety issues
The non-human primate studies are also essential to address the
questions of dosimetric and safety issues in the purpose of human
patients treatment. Studies using magnetic resonance imaging
show periodic displacements in the brain of up to 1 mm in humans
[55]. In the case of irradiation of non-human primates, the cyclic
motion of the brain, induced by cardiac vascular movements and
respiratory pulsations of the cerebrospinal ﬂuid, imposes efforts in
addition to those taken on the treatment planning for interlaced
microbeams in rodent animal models [56]. Since only one port can
be irradiated at a time, these movements must be understood in
detail to make them predictable and ensure that irradiations from
all ports happen at exactly the same point of the cyclic motion.
Otherwise the precisely interlaced beams may be shifted with
reference to each other and create gaps or overlapping areas
leading to an inhomogeneous dose deposition in the target area.
Monte Carlo dose calculations shall be used to accurately plan doses
applied to non-human primates, including effects of dose blurring
due to brain movement within one irradiation and movements in
between different ports. The results will need to be cross-checked
with experimental results from the irradiation of a suitable phan-
tom able to reproduce the ﬁne movements of a human brain. Using
non-human primates appears therefore necessary to implement
and validate all instrumental, dosimetric, safety and ethical aspects
to become as close as possible to clinical standards.
Hospital implementation
The European synchrotron X-ray source in Grenoble is for now
the only place in the World where preclinical trials using IntMRT
are carried out on a regular time basis. The ﬁrst technical de-
velopments of high ﬂux synchrotron X-ray microbeams have been
carried out for preclinical brain tumor radiation therapy. This
research domain is still active and promising enough for a realistic
clinical transfer in the years to come. The later application to the
epilepsy presented here reinforces the interest of such X-ray
sources in radiation therapy domain. These trials requires state-of-
the-art technical developments for imaging and X-ray dosimetry
control and are foreseen in others national or international X-ray
synchrotron sources. The encouraging preclinical results shown
here pave the way for future clinical applications using machines
available in clinics, i.e. outside the synchrotron scientiﬁc commu-
nity. The potential use of microbeam X-ray radiosurgery in the
hospital environment will depend mainly on the ability of new
table-top X-ray sources to produce sufﬁcient dose-rates to perform
radiosurgical procedures at acceptable cost.
Different projects aiming to build such table-top powerful X-ray
sources have been funded at least in three countries: US, Germany
and France. As a result extensive preclinical trials using this table-
top X-ray sources are to be encouraged and foreseen.
Conclusions
In this article we review several studies in animal models of
epilepsy which show the great interest of Interlaced MicrobeamRadiotherapy to block the synchronization of epileptic neuronal
networks. These studies showed also the limits of these techniques
by revealing the variability of their application to small irregularly
shaped sub-cortical structures in the mice which do not allow a
sufﬁcient targeting accuracy. There is now a need to continue to
apply IntMRT to rat models of epilepsy closer to the more severe
forms of human epilepsy and to implement such radiosurgery
approach to non-human primate models of epilepsy as a proof-of-
concept of its feasibility in human patients.
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